<< Back to the abstract archive
Treatment With Natural Berry Extract Sensitizes Endothelial Cell Tumors To The Effects Of Low Dose Radiation
Ayan Biswas, Kanhaiya Singh, Chandan K Sen, Gayle M Gordillo.
University
2019-02-15
Presenter: Ayan Biswas
Affidavit:
I certify that this work never been published in any scientific journal.
Director Name: Gayle M Gordillo
Author Category: Other Specialty Resident
Presentation Category: Basic Science Research
Abstract Category: General Reconstruction
Treatment of tumor forming endothelial (EOMA) cells with natural berry extracts (NBE) has been shown to induce apoptotic cell death through nuclear accumulation of oxidized proteins. Radiation therapy increases oxidation resulting in cellular apoptosis. We hypothesized that NBE treatment synergizes effects of radiation on endothelial cell tumors.
EOMA cells were treated with NBE (50 µg/ml) or vehicle control (1% DMSO). In vitro dose response curve (160 kV x-rays) identified the lowest effective radiation dose. Mice with EC tumors were given 3 doses (2.5Gy each) radiation and treated daily with NBE (200 mg/kg topical + 20 mg/kg oral). Tumor volume and blood flow were measured by ultrasound.
NBE treatment of EOMA cells resulted in significant increase in cell death in a dose-dependent manner for 0, 0.5 and 1Gy radiation with no evidence of toxicity in non-tumor forming MAE cells measured by LDH assay. Oxygen consumption/ basal respiration were 3 times higher in untreated EOMA vs. MAE cells. EOMA treatment with NBE or radiation resulted in a significant decrease in basal respiration, ATP production and mitochondrial membrane potential compared to MAE cells. These effects were synergistic with NBE and radiation combination. EOMA cell injection in 129 P/3 mice generated hemangioendothelioma tumors. Radiation did not decrease tumor size (n=5/group). Treatment with NBE significantly decreased tumor size. The combination resulted in tumors significantly smaller than NBE alone.
In summary, use of NBE may make radiation a potentially safe therapeutic option for life threatening endothelial cell tumors.
